Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion is poised for success with its focus on developing innovative treatments for diabetes and obesity, led by its promising lead asset icovamenib that targets the protein menin. With positive Phase 2b data expected in 2026 and a projected growing global market, the company has strong potential for success, yet there are risks involved in the development and commercialization process that should be considered by investors. In addition, the company's expansion plans into Europe could further increase its market reach and potential for growth.

Bears say

Biomea Fusion is a biotech company with a high risk profile due to its focus on earlier pipeline opportunities and limited commercialization potential in the highly competitive diabetes market. Additionally, the company has faced issues with its lead drug candidate, icovamenib, which has been placed on clinical hold by the FDA due to dose-related liver enzyme elevations. This, along with the potential for negative results in upcoming Phase 2 trials, could lead to significant setbacks for the company and hinder their attempts to address the growing need for innovative solutions for diabetes.

BMEA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Strong Buy based on their latest research and market trends.

According to 5 analysts, BMEA has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.